Surgical Science (Q2 Review): Delivering on its promises - Redeye
Bildkälla: Stockfoto

Surgical Science (Q2 Review): Delivering on its promises - Redeye

SUS delivered a strong Q2, beating expectations on both sales and EBIT. Encouragingly, the development with Intuitive continues to be better than feared. The share rallied more than 20% during the day, but we continue to see significant re-rating potential.

SUS delivered a strong Q2, beating expectations on both sales and EBIT. Encouragingly, the development with Intuitive continues to be better than feared. The share rallied more than 20% during the day, but we continue to see significant re-rating potential.
Börsvärldens nyhetsbrev